(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns - 2In a scientific first, biologists recorded a wild wolf potentially using tools
- 313 must-see moon events in 2026: Eclipses, supermoons, conjunctions and more
- 4Top 5 Top of the line Books of the Year
- 56 US States for Fly Fishing
- 6 Hints to Upgrade Your Charm, In addition to Your Mentality
- Seoul says sorry after unapproved drone flights into North Korea
- Aluminum salts emerge as likely target as health officials scrutinize childhood vaccines
- Culinary Joys: Investigating Connoisseur Cooking at Home
- Israeli strikes on Beirut, as Hezbollah and Iran attack Israel
- Gym tied to outbreak of obscure disease that spreads through mist
- Hyundai Is Keeping the i30 Alive While America Keeps Losing Cars Like It
- Manual for extravagance SUVs for seniors
- A Timeline of Rising Antisemitism in Australia
